Published Trials

AGO-OVAR 1/2

Phase I/II study of the combination of carboplatin and paclitaxel as first-line therapy patients with advanced epithelial ovarian cancer

A. du Bois, H.-J. Lück, T. Bauknecht, V. Möbus, H. Bochtler, K. Diergarten & H.-G. Meerpohl

Annals of Oncology 8: 335-361 (1997)

AGO-OVAR 3

A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

du Bois A, Lück H.-J, Meier W, Adams H-P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, for the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

J Natl Cancer Inst 2003; 95:1320-30

AGO-OVAR 4

First-line chemotherapy with epirubicin, paclitaxel, and Carboplatin (ET-Carbo) for advanced ovarian carcinoma. A phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

A du Bois, HJ Lück, T Bauknecht, W Meier, B Richter, J Pfisterer, J Quaas, W Kuhn

J Clin Oncol 17: 46-51, 1999

AGO-OVAR 5

Addition of epirubicin as third drug to carboplatin-paclitaxel in firstline treatment of advanced ovarian cancer. …

du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats Jean-Claude, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W, Kimmig R, Pujade-Lauraine E for AGO-OVAR and GINECO

J Clin Oncol 24: 1127-1135

AGO-OVAR 6

Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group

Pfisterer J, du Bois A, Wagner U, Quaas J, Blohmer JU, Wallwiener D and Hilpert F

Gynecologic Oncology 92 (2004) 949-956

AGO-OVAR 7

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer

Intergroup Trial of the AGO-OVAR and GINECO

Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E for the AGO-OVAR and GINECO

J Natl Cancer Inst 2006; 98:1036-1045

AGO-OVAR 8

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)

du Bois A, Belau A, Wagner U, Pfisterer J , Schmalfeldt B, Richter B, Stähle A, Jackisch C, Lueck H-J, Schroeder W, Olbricht S, Elser G and for the Arbeitsgemeinschaft Gyneaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

Gynecol Oncol 96 (2005) 444-451

AGO-OVAR 9

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer

du Bois A, Herstedt J, Hardy-Bessard A-C, Müller H-H, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J

J Clin Oncol 28: 4162-4169 (2010)

AGO-OVAR 10

Abagovomab as Maintenance Therapy in Patients with Epithelial Ovarian Cancer (MIMOSA Study): A Phase III Trial of the AGO OVAR,
COGI, GINECO, and GEICO – The MIMOSA Study

Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J

J Clin Oncol 2013: 1554-1561

AGO-OVAR 11

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Perren, TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar M KB, Oza AM, for the ICON7 Investigators

N Engl J Med 2011;365:2484-96

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T

Lancet Oncol 2013;14: 236-243

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon T-W, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MKB, Perren TJ, for the ICON7 trial investigators

Lancet Oncol 2015;16:928-36

AGO-OVAR 11t

Specialized histopathological second assessment of advanced ovarian cancer

S. Kommoss, J. Pfisterer, A. du Bois, D. Schmidt, F. Kommoss

Pathologe 2014, 35:355-360

Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtype

Kommoss S, Winterhoff B, Oberg AL, Konecny G, Wang C, Riska SM, Fan JB, Maurer MJ, Craig A, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, Schröder W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC and Pfisterer J

Clin Cancer Res 2017 Jul 15;23(14):3794-3801

AGO-OVAR 12

AGO-OVAR 12: A Randomised Placebo-Controlled GCIG/ENGOT-Intergroup Phase III Trial of Standard Frontline Chemotherapy +/- Nintedanib for Advanced Ovarian Cancer

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidzinski M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Sambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P, on behalf of the AGO Study Group led Gynecologic Cancer Intergroup (GCIG) / European Network of Gynaecologic Oncology Trials Group (ENGOT) Intergroup Consortium

The Lancet Oncology, Vol 17, No. 1, p78–89, January 2016

Published online November 15, 2015
DOI: http://dx.doi.org/10.1016/S1470-2045(15)00366-6

 

Nintedanib and ovarian cancer: standardise surgery in trials?

Kehoe S

Published online November 15, 2015: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00398-8/fulltext

AGO-OVAR 15

Randomized Phase II Trial of Carboplatin and Paclitaxel with or without Lonafarnib in First-Line Treatment of Epithelial Ovarian Cancer Stage IIB-IV

Meier W, du Bois A, Rau J, Gropp M, Baumann KH, Huober J, Wollschlaeger K, Kreienberg R, Canzler U, Schmalfeldt B, Wimberger P, Richter B, Schröder W, Belau A, Stähle A, Burges A, Sehouli J

Gynecologic Oncology 126 (2012) 236–240

AGO-OVAR 16

Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

du Bois A, Floquet A, Kim J-W, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier M-A, Kim J-H, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim B-G, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Cressenzo R, Harter P

J Clin Oncol. 2014 Oct 20; 32:3374-82, doi: 10.1200/JCO.2014.55.7348, Epub 2014 Sep 15

Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR 16 trial

Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Ionishi S, Crescenzo R J, Barrett C, Wang K, Mitrica I, du Bois A

Gynecologic Oncology 136 (2015) 37-42, DOI: https://www.gynecologiconcology-online.net/article/S0090-8258(14)01547-9/fulltext

BRCA1/2 mutations associated with progression free survival in ovarian cancer patients in the AGO-OVAR 16 study

Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, del Campo JM, Shimada M, Forget F, Mirza MR, Colombo N, Zamagni C, Chan JK, Imhof M, Herzog TJ, O’Donnell D, Heitz F, King K, Stinnett S, Barrett C, Jobanputra M, XU CF, du Bois A

Gynecol Oncol 2016 Mar; 140(3): 443-9. doi: 10.1016/j.ygyno.2015.12.027. Epub 2015 Dec 29

Communicating BRCA Research Results to Patients Enrolled in International Clinical Trials: Lessons Learnt From the AGO-OVAR 16 Study

Pulford D, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox Ch, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A

BMC Medical Ethics (2016) 17:63, DOI: 10.1186/s12910-016-0144-y

Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters – patient-centered end points in trials of maintenance therapy

Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A

Annals of Oncology 29: 737-743, 2018

doi:10.1093/annonc/mdx796

Published online 18 December 2017

AGO-OVAR 17 / BOOST

Optimal Treatment Duration of Bevacizumab as First-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

Pfisterer J, Joly F, Kristensen GB, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner M, Hartkopf A, Bauman K, Hasenburg A, Hanker L, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch W, de Gregorio N, Hilpert F, Harter P

Journal of Clinical Oncology 2023 41:4, 893-902.
DOI: 10.1200/JCO.22.01010
Published online November 04, 2022.

AGO-OVAR 18 / TRINOVA 3

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Vergote I, Scambia G, O’Malley DM, van Calster B, Park SY, del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Mirza MR, Kroep JR, Ma H, Pickett CA, Monk BJ

Lancet of Oncology; online first; Published May 7, 2019
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30178-0/fulltext

AGO-OVAR 20 / PAOLA-1

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Ray Coquard I, Pautier P, Pignata S, Pérol D, González Martín A, Berger R, Fujiwara K, Vergote I, ColomboN, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía E M, Reinthaller A, Nagao S, Lefeuvre Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade Lauraine E, and Harter P for the PAOLA-1 Investigators

N Engl J Med 2019;381:2416-28.
DOI: 10.1056/NEJMoa1911361

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martin A, Bogner G, Fujiwara K, Vergote I, Colombo N, Jakobi Nøttrup T, Floquet A, El-Balat A, Scambia G, Guerra-Alia EM, Fabbro M, Schmalfeldt B, Hardy-Bessard AC, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I

Gynecologic Oncology 164 (2022) 254-264

Published online: Dec 22, 2021
https://doi.org/10.1016/j.ygyno.2021.12.016

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: Phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martin-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL

Annals of Oncology,
Volume 34, Issue 2,2023,pp:152-162
online 28 November 2022
https://doi.org/10.1016/j.annonc.2022.11.003 

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martin A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpäaa J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P

Annals of Oncology – Volume 34, Issue 8, P681-692, August 2023
Published online: May 19, 2023
DOI:https://doi.org/10.1016/j.annonc.2023.05.005

 

AGO-OVAR 21 / PRIMA

Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Mirza MR, González-Martín A, Graybill WS, O’Malley D, Gaba L, Yap OWS, Guerra EM, Rose PG, Burain JF, Ghamande SA, Denys H, Prendergast E, Pisano C, Follana P, Baumann K, Calvert PM, Korach J, Li Y, Malinowska IA, Gupta D, Monk BJ

Cancer. 2023; 1- 10. doi:10.1002/cncr.34706

Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

Gonzalez Martin, A.J, Pothur B, Vergote IB, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O’Cearbhaill RE, Malinowska I, Shtessel L, Compton N, Mirza MR, Monk BJ

European Journal of Cancer 189 (2023) 112908
DOI: https://doi.org/10.1016/j.ejca.2023.04.024 Published online: May 02, 2023

AGO-OVAR 22 / IMagyn050

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore, MD; Michael Bookman, MD; Jalid Sehouli, MD; Austin Miller, PhD; Charles Anderson, MD; Giovanni Scambia, MD; Tashanna Myers, MD; Cagatay Taskiran, MD; Katina Robison, MD; Johanna Mäenpää, MD; Lyndsay Willmott, MD; Nicoletta Colombo, MD; Jessica Thomes-Pepin, MD; Michalis Liontos, MD; Michael A. Gold, MD; Yolanda Garcia, MD; Sudarshan K. Sharma, MD; Christopher J. Darus, MD; Carol Aghajanian, MD; Aikou Okamoto, MD; Xiaohua Wu, MD; Rustem Safin, MD; Fan Wu, MS; Luciana Molinero, MD; Vidya Maiya, MD; Victor K. Khor, PhD; Yvonne G. Lin, MD; and Sandro Pignata, MD

Journal of Clinical Oncology; Published at ascopubs.org/journal/jco on April 23, 2021:
DOI https://doi.org/10.1200/JCO.21.00306

AGO-OVAR 25 / ATHENA

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Monk BJ, Parkinson C, Lim MC, O’Malley DM, Oaknin A, Wilson MK, Colemann RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtej V, Barlin JN, van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Morre K, Marmé F, Westin SN McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS

Journal of Clinical Oncology 40, no. 34 (December 01, 2022) 3952-3964
Published online June 06, 2022
DOI: 10.1200/JCO.22.01003

AGO-OVAR 2.1

Chemotherapy versus Hormonal Treatment in Platinum- and Paclitaxel-Refractory Ovarian Cancer: A Randomized Trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer

A du Bois, W Meier, HJ Lück, G Emons, V Möbus, W Schröder, S Costa, T Bauknecht, S Olbricht, C Jackisch, B Richter, U Wagner

Annals of Oncology 13:251-257,2002

AGO-OVAR 2.2

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR 2.2 trial

The ICON and AGO Collaborators (writing committee)

Lancet 361: 2099-2106 (2003)

AGO-OVAR 2.3

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

W Meier, A du Bois, A Reuss, W Kuhn, S Olbricht, M Gropp, B Richter, HJ Lück, R Kimmig, J Pfisterer

Gynecologic Oncology 114 (2009) 199-205

AGO-OVAR 2.4

2nd-line chemotherapy with carboplatin and gemcitabine in patients with platinum sensitive recurrent ovarian cancer. A phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

A du Bois, HJ Lück, J Pfisterer, W Schroeder, JU Blohmer, R Kimmig, V Moebus, J Quaas

Annals of Oncology 12: 1115-1120, 2001
W Meier, A du Bois, A Reuss, W Kuhn, S Olbricht, M Gropp, B Richter, HJ Lück, R Kimmig, J Pfisterer

Gynecologic Oncology 114 (2009) 199-205

AGO-OVAR 2.5

Gemcitabine plus carboplatin versus carboplatin in patients with platinum-sensitive-recurrent ovarian cancer

Pfisterer J, Plante M, Vergote I, Zimmerman A, du Bois A, Hirte H, Lacave A J, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück H-J, Rochon J, Zimmermann A H, Eisenhauer E for the AGO OVAR, NCIC CTG and EORTC GCGPfisterer J, Plante M, Vergote I, Zimmerman A, du Bois A, Hirte H, Lacave A J, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück H-J, Rochon J, Zimmermann A H, Eisenhauer E for the AGO OVAR, NCIC CTG and EORTC GCG

J Clin Oncol 24:4699-4707, 2006

AGO-OVAR 2.6

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy – A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)

Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Lück HJ, Sehouli J, Gropp M, Stähle A, Schmalfeldt, B, Meier W, Jackisch C

Gynecol Oncol 2007; 105:132-137

AGO-OVAR 2.8

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer – A phase I trial of the AGO-OVAR

Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuß A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert , On behalf of the AGO-OVAR

Ann Oncol 17: 1568-1577, 2006

AGO-OVAR 2.9

Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel an carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey P A, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, and du Bois A

J Clin Oncol 28:3323-3329, 2010

AGO-OVAR 2.9

Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel an carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey P A, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, and du Bois A

J Clin Oncol 28:3323-3329, 2010

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell’Anna T, Cretin J, Havsteen H, Besette P, Zeimet AG, Vergote I, Vasey P, Pujade-Lauraine E, Gladieff L, Ferrero AM

European Journal of Cancer (2015) 51, 352-358

AGO-OVAR 2.10

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group

Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Vergote I, Lück HJ, Wagner U

Gynecol Oncol 2011; 123:27-32

AGO-OVAR 2.11

A Phase II Trial (AGO 2.11) in platinum resistant Ovarian Cancer: a randomized multicenter trial with Sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

Baumann K, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U

Annals of Oncology 23:2265-2271, 2012

AGO-OVAR 2.12

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)

Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W

Ann Oncol. (2016) 27 (12):2236-2241

AGO-OVAR 2.13

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

Philipp Harter, Jalid Sehouli, Rainer Kimmig, Jörn Rau, Felix Hilpert, Christian Kurzeder, Gabriele Elser, Andreas du Bois

Invest New Drugs (2013) 31:1499-1504

AGO-OVAR 2.15

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I on behalf of the ENGOT-GCIG investigators

J Clin Oncol 32:1302-1308, 2014; DOI:10.1200/JCO.2013.51.4489

AGO-OVAR 2.15

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I on behalf of the ENGOT-GCIG investigators

J Clin Oncol 32:1302-1308, 2014; DOI:10.1200/JCO.2013.51.4489

Patient reported outcome resuluts from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer

Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee C, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E

J Clin Oncol 43:1309-1316,2014; DOI: 10.1200/JCO.2013.51.4240

Editorial Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

Joyce F. Liu and Stephen A. Cannistra

J Clin Oncol 2014, Mar 17 [Epub ahead of print]; DOI:10.1200/JCO.2013.54.7299

Bevacizumab combined with weekly Paclitaxel, Pegylated Liposomal Doxurubicin, or Topotecan in platinum-resistend recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized Phase III AURELIA trial

Poveda A, Selle F, Hilpert F, Reuß A, Savarese A, Vergote I, Witteveen P, Bamias A, Scotto N, Mitchell L, Pujade-Lauraine E

J Clin Oncol 2015 33(32):3836-8

doi: 10.1200/JCO.2015.63.1408.Epub 2015 Aug 17
https://ascopubs.org/doi/full/10.1200/JCO.2015.63.1408

AGO-OVAR 2.16 / MITO 8

Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer

Pignata S, Scambia G, Bologna A, Signoriello S, Vergote I, Wagner U, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce JC, Gennaro D, Piccirillo MC, Gallo C, Perrone F

J Clin Oncol. 2017 Oct 10;35(29):3347-3353.

doi: 10.1200/JCO.2017.73.4293. Epub 2017 Aug 21

AGO-OVAR 2.17

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Amit M Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron HJ Mathijssen, Gabe S Sonke, Nicoletta Colombo, Jiri Spacek, Peter Vuylsteke, Holger Hirte, Sven Mahner, Marie Plante, Barbara Schmalfeldt, Helen Mackay, Jacqui Rowbottom, Elisabeth S Lowe, Brian Dougherty, J Carl Barrett, Michael Friedlander

The Lancet Oncology, Volume 16, Issue 1, 87 – 97
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71135-0/fulltext

AGO-OVAR 2.18/TRIAS

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, de Gregorio N, Fridrich C, Markmann S, Potenberg P, Lorenz R, Oskay-Oezcelik G, Schmidt M, Krabisch P, Lueck HJ, Richter R, Braicu EI, du Bois A, Sehouli J

The Lancet Oncology, DOI: https://doi.org/10.1016/S1470-2045(18)30372

AGO-OVAR 2.19/TRINOVA-2

ENGOT-ov-6/TRINOVA-2: Randomized, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Sevilay A, Rustin G, Wenham RM, Mirza M, Fong PC, Oza A, Monk BJ, Ma H, Vogl FK, Bach BA

European Journal of Cancer 70 (2017) 111-121
https://www.ejcancer.com/article/S0959-8049(16)32425-X/fulltext

AGO-OVAR 2.20

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)

Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, del Campo JM, Mahner S, Bastiere-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A and Gonzalez-Martin A

J Clin Oncol. 2016 Jul 20;34(21):2516-25. doi:10.1200/JCO.2015.66.0787. Epub 2016 Jun 6

Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial

González-Martín A, Pautier P, Mahner S, Rau J, Colombo N, Ottevanger P, del Campo JM, Selle F, du Bois A, Gadducci A, Garcia Y, Berton-Rigaud D, Marmé F, Ortega E, Martin N, Bastiere-Truchot L, Kiermaier A, Kurzeder C

Int J Gynecol Cancer. 2016 Jun;26(5):898-905. doi: 10.1097/IGC.0000000000000695

AGO-OVAR 2.21

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean, Alexander Hein, Alain G Zeimet, Lars C Hanker, Thierry Petit, Frederik Marmé, Ahmed El-Balat, Rosalind Glasspool, Nikolaus de Gregorio, Sven Mahner, Tarek M Meniawy, Tjoung-Won Park-Simon, Marie-Ange Mouret-Reynier, Cristina Costan, Werner Meier, Alexander Reinthaller, Jeffrey C Goh, Tifenn L’Haridon, Sally Baron Hay, Stefan Kommoss, Andreas du Bois, Jean-Emmanuel Kurtz, for the AGO-OVAR 2.21/ENGOT-ov 18 Investigators

Lancet Oncol 2020

Published Online April 16, 2020 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30142-X/fulltext

AGO-OVAR 2.22/NOVA

Niraparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

Mirza MR, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A, Fabbro M, Ledermann J, Lorusso K, Vergote I, Ben-Baruch EN, Marth C, Madry R, Christensen.., Berek J, Dørum A, Tinker A, du Bois A, Gonzalez M, Fallana P, Benigno B, Rosenberg P, Gilbert L, Rimel B, Buscema J, Balser J, Agarwal S, Matulonis U

N Engl J Med 2016; Published online 8. Oktober 2016

DOI 10.1056/NEJMoa1611310

AGO-OVAR 2.23/SOLO 2

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P, the SOLO2/ENGOT-Ov21 investigators

Published Online July 25, 2017 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30469-2/fulltext

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S Sonke, Alla Lisyanskaya, Jae-Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S Lowe, Phil Rowe, Ignace Vergote, Eric Pujade-Lauraine, the SOLO2/ENGOT-Ov21 investigators

Published online March 18, 2021 https://doi.org/10.1016/S1470-2045(21)00073-5

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

Trillsch F, Mahner S, Ataseven B, Asher R, Aryal N, Dubot C, Clamp A, Penson RT, Oza A, Amit A, Huzarski T, Casado A, Scambia G, Friedlander M, Colombo N, Fujiwara K, Sonke GS, Denys H, Lowe ES, Lee CK, Pujade-Lauraine E

Gynecol Oncol. 2022 Apr;165(1):40-48. doi: 10.1016/j.ygyno.2022.01.024.
Epub 2022 Jan 31

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer

Francis KE, Kim SI, Friedlander M, Gebski V, Ray-Coquard I, Clamp A, Penson RT, Oza A, Perri T, Huzarsk T, Martin-Lorente C, Cecere SC, Colombo N, Ataseven B, Fujiwara K, Sonke G, Pujade-Lauraine E, Kim JW, Lee CK

Annals of Oncology, 2022, Volume 33, Issue 6, 593 – 601
https://doi.org/10.1016/j.annonc.2022.02.222

AGO-OVAR 2.25/GANNET53

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer – A Study of the GANNET53 Consortium

Isabelle Ray-Coquard, Ioana Braicu, Regina Berger, Sven Mahner, Jalid Seouli, Eric Pujade-Lauraine, Philippe Alexandre Cassier, Ute Martha Moll, Hanno Ulmer, Karin Leunen, Alain Gustave Zeimet, Christian Marth, Ignace Vergote and Nicole Concin on behalf of the entire GANNET53 Consortium (18 Partner Institutions in Europe)

Front. Oncol. 9:832. doi: 10.3389/fonc.2019.00832

AGO-OVAR 2.30/ATALANTE

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean-Emmanuel Kurtz, MD, PhD; Eric Pujade-Lauraine, MD; Ana Oaknin, MD; Lisa Belin, MSc; Katharina Leitner, MD; David Cibula, MD; Hannelore Denys, MD; Ora Rosengarten, MD; Manuel Rodrigues, MD; Nikolaus de Gregorio, MD; Jeronimo Martinez García, MD ; Edgar Petru, MD; Roman Kocián, MD; Ignace Vergote, MD; Patricia Pautier, MD; Barbara Schmalfeldt, MD; Lydia Gaba, MD; Stephan Polterauer, MD; Marie-Ange Mouret Reynier, MD; Jalid Sehouli, MD; Cristina Churruca, MD; Frédéric Selle, MD; Florence Joly, MD; Véronique D’Hondt, MD; Émilie Bultot-Boissier, MD; Coriolan Lebreton, MD; Jean-Pierre Lotz, MD; Rémy Largillier, MD29; Pierre-Etienne Heudel, MD; and Florian Heitz, MD; on behalf of the ATALANTE/ENGOT-ov29 Investigators

Journal of Clinical Oncology 2023 41:30, 4768-4778,  Published August 29, 2023

AGO-OVAR 2.31/OReO

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A, on behalf of the OReO/ENGOT-ov38 investigators

Annals of Oncology (2023), Published 3. October 2023
DOI:https://doi.org/10.1016/j.annonc.2023.09.3110

 

AGO-OVAR 2.38/SORAYA

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

Matulonis U, Lorusso D, Oakinin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Romeo M, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL

Journal of Clinical Oncology 2023 41:13, 2436-2445
DOI: 10.1200/JCO.22.01900
Published online January 30, 2023.

AGO-GYN 2

Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)

A. du Bois, A. Burges, W. Meier, J. Pfisterer, B. Schmalfeldt, B. Richter, C. Jackisch, A. Staehle, R. Kimmig & G. Elser on behalf of AGO-OVAR Germany

Annals of Oncology 17: 93-96, 2006

AGO-GYN 3

Combination Therapy with Pegylated Liposomal Doxorubicin and Carboplatin in Gynecologic Malignancies: A Prospective Phase-II Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut)

du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Staehle A, Jackisch C, Koelbl H

Gynecol Oncol 2007; 107: 518-525

AGO-GYN 4

A Phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S Reichardt V, Harter P

Annals of Oncol 2010 21:370-375

AGO-GYN 5

Efficiacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors, A Multicenter Phase 2 Trial (AGO-GYN 5)

Günter Emons, Grigor Gorchev, Philipp Harter, Pauline Wimberger, Anne Stähle, Lars Hanker, Felix Hilpert, Matthias W. Beckmann, Peter Dall, Carsten Gründker, Herbert Sindermann, Jalid Sehouli

Int J Gynecol Cancer 2014; 24, Number 2: 260-265

Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)

Günter Emons, Grigor Gorchev, Jalid Sehouli, Pauline Wimberger, Anne Stähle, Lars Hanker, Felix Hilpert, Herbert Sindermann, Carsten Gründker, Philipp Harter

Gynecol Oncol 133 (2014): 427-432

AGO-GYN 6

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group
du Bois A, Vergote I, Wimberger P, Ray-Coquard I, Harter P, Baylor Curtis L, Mitrica I

British Journal of Cancer 2012; 106, 629-632

AGO-GYN 7

Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors

A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7)

Philipp Harter, Jalid Sehouli, Alexander Reuss, Klaus Baumann, Lars Hanker, Rainer Kimmig, Willibald Schröder, Alexander Burges, Martina Gropp-Meier, Christian Kurzeder, Sven Mahner, Ulrich Canzler, Hans-Joachim Lück, Werner Meier, Tanja Fehm, and Andreas du Bois

Int J Gynecol Cancer. 2016 Nov; 26(9):1636-1641. DOI:10.1097/IGC.0000000000000831. Epub 2016 Sep 19

AGO-GYN 8

Temsirolismus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN 8)

Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F

Gynecol Oncol. 140 (2016) 450-456

AGO-GYN 9 / ALIENOR

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal TumorsThe ALIENOR/ENGOT-ov7 Randomized Clinical Trial

Isabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, Cécile Dalban, Ignace Vergote, Keiichi Fujiwara, Laurence Gladieff, Hans-Joachim Lück, Anne Floquet, Annick Chevalier-Place, Andreas Schnelzer, Sandro Pignata, Frédéric Selle, Jalid Sehouli, Fabien Brocard, Giorgia Mangili, Patricia Pautier, Ugo De Giorgi, Magali Provansal, Pierre-Etienne Heudel

JAMA Oncol. 2020;6(12):1923-1930. doi:10.1001/jamaoncol.2020.4574

AGO-EN 2 / AtTEnd

Atezolizumab and chemotherapy for advanced or recurrent  endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Colombo N, Biagioli E, Harana K, Galli F, Huson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Farinas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesata MP, and AtTEnd study group

Lancet Oncol 2024 , Published Online August 2, 2024

https://doi.org/10.1016/S1470-2045(24)00334-6

AGO-EN 3 / RUBY

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

M.R. Mirza, D.M. Chase, B.M. Slomovitz, R. dePont Christensen, Z. Novák, D. Black, L. Gilbert,
S. Sharma, G. Valabrega, L.M. Landrum, L.C. Hanker, A. Stuckey, I. Boere, M.A. Gold,
A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M.S. Shahin, S.E. Gill, B.J. Monk,
J. Buscema, T.J. Herzog, L.J. Copeland, M. Tian, Z. He, S. Stevens, E. Zografos, R.L. Coleman,
and M.A. Powell, for the RUBY Investigators

The New England Journal of Medicine, March 27, 2023, NEJM.org.
DOI: 10.1056/NEJMoa2216334

AGO-CaRE 1

Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study

Sven Mahner, Julia Jueckstock, Felix Hilpert, Petra Neuser, Philipp Harter, Nikolaus de Gregorio, Annette Hasenburg, Jalid Sehouli, Annika Habermann, Peter Hillemanns, Sophie Fuerst, Hans-Georg Strauss, Klaus Baumann, Falk Thiel, Alexander Mustea, Werner Meier, Andreas du Bois, Lis-Femke Griebel, Linn Woelber; for the AGO-CaRE 1 investigators

JNCI J Natl Cancer Inst (2015) 107(3):dju426

Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer

Eulenburg C, Suling A, Neuser B, Reuss A, Canzler U, Fehm T, Luyten A, Hellriegel M, Woelber L, Mahner S

PLoS ONE 11(11): e0165705.doi: 10.1371/journal.pone.0165705

Role of tumor-free margin distance for loco-regional control in vulvar cancer – a subset analysis of the AGO CaRE-1 multicenter study

Wölber L, Griebel LF, Eulenburg C, Sehouli J, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Ignatov A, Hillemanns P, Fürst S, Strauss HG, Baumann KH, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker LC, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Neuser P, Mahner S

European Journal of Cancer 69 (2016):180 – 188

https://www.ejcancer.com/article/S0959-8049(16)32484-4/fulltext

Outcome after Sentinel lymph node dissection in vulvar cancer. A subgroup analysis of the AGO-CaRE-1-study

Klapdor R, Hillemanns P, Jückstock J, Wölber L, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Habermann A, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Jäger M, Mahner S

Ann Surg Oncol (2017) 24:1314

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study

Plterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kölbl H, Reinthaller A, Woelber L, Mahner S

Gynecol Oncol 153 (2019) pp 286-291

AGO-VOP.2 / QS Vulva

Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 / QS Vulva

Woelber L, Hampl M, Eulenburg CZ, Prieske K, Hambrecht J, Fuerst S, Klapdor R, Heublein S, Gass P, Rohner A, Canzler U, Becker S, Bommert M, Bauerschlag D, Denecke A, Hanker L, Runnebaumn I, Forner DM, Schochter F, Klar M, Schwab R, Koepke M, Kalder M, Hantschmann P, Ratiu D, Denschlag D, Schroeder W, Tuschy B, Baumann K, Mustea A, Soergel P, Bronger H, Bauerschmitz G, Kosse J, Koch MC, Ignatov A, Sehouli J, Dannecker C, Mahner S, Jaeger A

Cancers (Basel). 2022 Jan 14;14(2):418
doi: 10.3390/cancers14020418

AGO-ZX 3 / BEATcc

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, de Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Jésus Rubio M, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo A, Yunokawa M, Dahlstrand H, D’Hondt V, Randall L for the ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030 Investigators

The Lancet, Published online December 1, 2023 https://doi.org/10.1016/S0140-6736(23)02405-4 

AGO-ZX 4

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators

N Engl J Med. 2024 Jul 4;391(1):44-55.

doi: 10.1056/NEJMoa2313811. 

AGO-OP.1 / DESKTOP I

Surgery in recurrent ovarian cancer – The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J. Heilmann V for the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee (AGO OC) and the AGO Ovarian Cancer Study Group (AGO-OVAR)

Ann Surg Oncol 2006 online first 10-2006

AGO-OP.2 / DESKTOP II

Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer
The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO

Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry K U, Obermair A, Petru E, Schmalfeldt B, Lorusso D, and du Bois A

Int J Gynecol Cancer 2011, 21: 289-295

AGO-OP.3 / LION

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

P. Harter, J. Sehouli, D. Lorusso, A. Reuss, I. Vergote, C. Marth, J.-W. Kim, F. Raspagliesi, B. Lampe, G. Aletti, W. Meier, D. Cibula, A. Mustea, S. Mahner, I.B. Runnebaum, B. Schmalfeldt, A. Burges, R. Kimmig, G. Scambia, S. Greggi, F. Hilpert, A. Hasenburg, P. Hillemanns, G. Giorda, I. von Leffern, C. Schade-Brittinger, U. Wagner, and A. du Bois

N Engl J Med 2019;380:822-32

AGO-OP.4 / DESKTOP III

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

P. Harter, J. Sehouli, I. Vergote, G. Ferron, A. Reuss, W. Meier, S. Greggi, B.J. Mosgaard, F. Selle, F. Guyon, C. Pomel, F. Lécuru, R. Zang, E. Avall‑Lundqvist, J.-W. Kim, J. Ponce, F. Raspagliesi, G. Kristensen, J.-M. Classe, . Hillemanns, P. Jensen, A. Hasenburg, S. Ghaem‑Maghami, M.R. Mirza, B. Lund, A. Reinthaller, A. Santaballa, A. Olaitan, F. Hilpert, and A. du Bois, for the DESKTOP III Investigators

N Engl J Med 2021;385:2123-31

AGO-OP.5 / ROBOT

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study

F Trillsch, S Mahner, E Vettorazzi, L Woelber, A Reuss, K Baumann, M-D Keyver-Paik, U Canzler, K Wollschlaeger, D Forner, J Pfisterer, W Schroeder, K Muenstedt, B Richter, C Fotopoulou, B Schmalfeldt, A Burges, N Ewald-Riegler, N de Gregorio, F Hilpert, T Fehm, W Meier, P Hillemanns, L Hanker, A Hasenburg, H-G Strauss, M Hellriegel, P Wimberger, S Kommoss, F Kommoss, S Hauptmann and A du Bois

British Journal of Cancer (2015), 1-7 doi: 10.1038/bjc.2014.648, Advance Online Publication: 6 January 2015

Corrigendum to “Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group” Eur J Cancer 49 (2013) 1905-1914

A du Bois, N Ewald-Riegler, N de Gregorio, A Reuss, S Mahner, C Fotopoulou, F Kommoss, B Schmalfeldt, F Hilpert T Fehm, A Burges, W Meier, P Hillemanns, L Hanker, A Hasenburg, H-G Strauss, M Hellriegel, P Wimberger, M-D Keyver-Paik, K Baumann, U Canzler, K Wollschlaeger, D Forner, J Pfisterer, W Schröder, K Münstedt, B Richter, S Kommoss, S Hauptmann

Eur J Cancer 65 (2016) 192-193

https://www.ejcancer.com/article/S0959-8049(16)32278-X/fulltext

AGO-OP.8 / SHAPE

Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer

Marie Plante, M.D., Janice S. Kwon, M.D., Sarah Ferguson, M.D., Vanessa Samouëlian, M.D., Gwenael Ferron, M.D., Amandine Maulard, M.D., Cor de Kroon, M.D., Willemien Van Driel, M.D., John Tidy, M.D., Karin Williamson, M.D., Sven Mahner, M.D., Stefan Kommoss, M.D., Frederic Goffin, M.D., Karl Tamussino, M.D., Brynhildur Eyjólfsdóttir, M.D., Jae-Weon Kim, M.D., Noreen Gleeson, M.D., Lori Brotto, Ph.D., Dongsheng Tu, Ph.D., and Lois E. Shepherd, M. for the CX.5 SHAPE investigators

N Engl J Med 2024;390:819-29.
DOI: 10.1056/NEJMoa2308900
https://www.nejm.org/doi/full/10.1056/NEJMoa2308900

 

Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial

Kwon JS, McTaggart-Cowan H, Ferguson SE, Samouelian V, Lambaudie E, Guyon F, Tidy J, Williamson K, Gleeson N, de Kroon C, van Driel W, Mahner S, Hanker L, Goffin F, Berger R, Eyjolsdottier B, Kim JW, Brotto LA, Pataky R, Yeung SST, Chan KKW, Cheung MC, Ubi J, Tu D, Sheperd L, Plante M

J Gynecol Oncol, 2024 Nov;35(6):e117
Published online: Oct 18, 2024
https://doi.org/10.3802/jgo.2024.35.e117

 

AGO-TR 1

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO TR-1)

Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R

PLoS ONE 12(10):e0186043, Published: October 20, 2017

https://doi.org/10.1371/journal.pone.0186043

Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: Results of the observational AGO-TR 1 study (NCT02222883)

Hauke J, Hahnen E, Schneider S, Reuss A, Richters LK, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, de Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Kimmig R, Dietrich D, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Hanker LC, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P

J Med Genet epub agead of print: April 2019

doi:10.1136/ jmedgenet-2018-105930

Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial

Schouten PC, Richters L, Vis DJ, Kommoss S, van Dijk E, Ernst C, Kluin RJC, Marmé F, Lips EH, Schmidt S, Scheerman E, Prieske K, van Deurzen CHM, Burges A, Ewing-Graham PC, Dietrich D, Jager A, de Gregorio N, Hauke J, du Bois A, Nederlof PM, Wessels LF, Hahnen E, Harter P, Linn SC, Schmutzler RK

Clin Cancer Res. 2021 Dec 1;27(23):6559-6569
doi: 10.1158/1078-0432.CCR-21-1673
Epub 2021 Sep 30

Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883)

Hauke J, Harter P, Ernst C, Burges A, Schmidt S, Reuss A, Borde J, de Gregorio N, Dietrich D, El-Balat A, Kayali M, Gevensleben H, Hilpert F, Altmüller J, Heimbach A, Meier W, Schoemig-Markiefka B, Thiele H, Kimmig R, Nürnberg P, Kast K, Richters L, Sehouli J, Schmutzler RK, Hahnen E

J Med Genet. 2022 Mar;59(3):248-252.
doi: 10.1136/jmedgenet-2020-107353. Epub 2020 Dec 3.

Therapy of advanced ovarian cancer in Germany: What is the impact of participation in clinical trials?

Results of a survey by the ORGANKOMMISSION OVAR of the Working Group on Gynecological Oncology (AGO) in the German Society of Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG)

A. du Bois, J. Pfisterer, Lenka Kellermann, R. Kreienberg

Geburtsh Frauenheilk 2001; 61: 863-871 © Thieme Verlag Stuttgart – New York – ISSN 0016-5751

QS-OVAR 2001

The Quality Assurance Program of the AGO Organkommission OVAR (QS-OVAR): Care Structure and Reality in Germany 2001.

Analysis of the care structure and quality of ovarian cancer therapy in Germany. Examination of the extent to which the therapy guidelines are implemented, and description of prognostic factors.

A. du Bois, J. Rochon, C. Lamparter, J. Pfisterer

Zentralbl Gynakol 2005; 127: 9–17 · © J. A. Barth Verlag in Georg Thieme Verlag KG DOI 10.1055/s-2005-836289 ISSN 0044-4197

What influence do clinic characteristics have on prognosis in ovarian cancer in Germany?

Analysis of the association between clinic characteristics on treatment quality and outcomes in ovarian cancer in Germany.

A. du Bois, J. Rochon, C. Lamparter, J. Pfisterer für die AGO Organkommission OVAR

Zentralbl Gynakol 2005; 127: 18–30 · © J. A. Barth Verlag in Georg Thieme Verlag KG DOI 10.1055/s-2005-836290 ISSN 0044-4197

Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO-Study Group

Wimberger P, Pfisterer J, du Bois A, Hilpert F, Kerkmann M, Sehouli J, Mahner S, de Gregorio N, Hanker L, Heitz F, Marmé F, Wölber L, Holtmann L, Elser G, Harter P

International Journal of Gynecologic Cancer 2023;33:1083-1089
Published Online First: 31 March 2023. doi: 10.1136/ijgc-2022-004233

Advanced epithelial ovarian cancer: 1998 consensus statement

J.S. Berek, K. Bertelsen, A. du Bois, M.F. Brady, J. Carmichel, E.A. Eisenhauer, M. Gore, S. Grenman, T.C. Hamilton, S. W. Hansen, P.G. Harper, G. Horvath, S.B. Kaye, H.J. Lück, B. Lund, W.P. McGuire, J.P. Neijt, R.F. Ozols, M.K.B. Parmar, M.J. Piccart-Gebhart, R. van Rijswijk, P. Rosenberg, G.J.S. Rustin, C. Sessa, J.T. Thigpen, C. Tropé, M.K. Tuxen, I. Vergote, J.B. Vermorken, & P.H.B. Willemse

Ann Oncol 10 (suppl. 1): S87-S92 (1999)

Is efficient clinical research in gynecologic oncology possible in Germany

History and current status using the AGO ovarian cancer trials as an example. A statement of the AGO Ovarian Cancer Study Group.

du Bois A, Studiengruppe Ovarialkarzinom der Arbeitsgemeinschaft gynäkologische Onkologie (AGO)

Forum DKG 14: 815-824 (1999)

Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Undergoing Platinum/Paclitaxel-Containing First-Line Chemotherapie:

An Exploratory Analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group

Christina Fotopoulou, Andreas du Bois, Alexandros N. Karavas, Ralf Trappe, Behnaz Aminossadati, Barbara Schmalfeldt, Jacobus Pfisterer and Jalid Sehouli

J Clin Oncol 26 (16): 2683-2689

AGO-OVAR 3/QoL

Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel

Elfriede R. Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, Felix Hilpert, Fedor Daghofer and Andreas du Bois

J Clin Oncol 24 (4): 579-586

AGO-OVAR 3 / Her-2/neu

Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First Line Chemotherapy. A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO-OVAR Germany

Pfisterer J, du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F

Int J Gynecol Cancer 2009; 19:109-115

AGO-OVAR 14

Non-enrollment of ovarian cancer patients in clinical trials: Reasons and Backgrounds

Harter P, du Bois A, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Schmalfeldt B, Huober J, Staehle A, Pfisterer J for the Study Coordination Group of the AGO-OVAR

Ann Oncol 16: 1801-1805, 2005

Neurotox

Neuroprotection with amifostine in the 1st-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy – a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group

Hilpert F, Stähle A, Tomé O, Burges A, Rossner D, Späthe K, Heilmann V, Richter B and du Bois A for the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) ovarian cancer study group

Support Care Cancer 2005 Oct; 13(10): 797-805

Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer

Mackay H J, Brady M F, Oza A M, Reuss A, Pujade-Lauraine E, Swart A M, Siddiqui N, Colombo N, Bookman M A, Pfisterer J, du Bois A on behalf of the Gynecologic Cancer InterGroup (2010)

Int J Gynecol Cancer 20:945-952;2010

European network of gynaecological oncological trial groups’ requirements for trials between academic groups and pharmaceutical companies

Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AGJ, du Bois A

Int J Gynecol Cancer 20:476-478;2010

CA125 Early decline as a surrogate for progression-free survival in recurrent ovarian cancer

Lee CK, Friedlander M, Brown Ch, Gebski V, Georgopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza Mr, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes J

J Natl Cancer Inst 2011;103:1-5

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to Carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial

Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Bomann K, Sugimoto A, Vaughan M, Reinthaller A, Vergote I, Ferrandina G, Dell’Anna T, Huober J, Pujade-Lauraine E

Gyn Oncol 2011;122(2):226-32

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a GCIG CALYPSO sub-study

Kurtz JE, Kaminski MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E on Behalf of Gynecologic Cancer Intergroup

Ann Oncol 2011 (Epub ahead of print)

The European network of Gynaecological Oncological Trial Groups

Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee AGJ, du Bois A

Clin.Invest. (2012) 2(1), 35-37

Treatment of Elderly Ovarian Cancer Patients in the Context of Controlled Clinical Trials: A Joint Analysis of the AGO Germany Experience

Hilpert F, Wimberger P, du Bois A, Pfisterer J, Harter P

Onkologie 2012;35:76–81

Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials

Ignace Vergote, MD, PhD, Gabriele Elser, RN, Benedicte Votan, MSc, Laura Farrelly, BSc(hons), RN, Joke De Roover, PhD, Jane Bryce, RN, MSN, Andreas du Bois, MD, PhD, and On Behalf of the member trial groups of the European Network of Gynaecological Trial groups (ENGOT)

Int J Gynecol Cancer 2013;23: 1339-1343

Specialized Pathology Review in Patients With Ovarian Cancer, Results From a Prospective Study

Stefan Kommoss, MD, Jacobus Pfisterer, MD, Alexander Reuss, MSc, Joachim Diebold, MD, Steffen Hauptmann, MD, Christine Schmidt, MD, Andreas du Bois, MD, Dietmar Schmidt, MD, and Friedrich Kommoss, MD

Int J Gynecol Cancer 2013;23: 1376-1382

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: A sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT Study

Trillsch F, Mahner S, Woelber L, Vettarazzi E, Reiss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik DM, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A

Annals of Oncology 25:1320-1327.2014

Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients

Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J.

Eur J Cancer. 2015.2015 May;51(7):825-32

The European Network for Gynaecological Oncological Trial Groups Charta for Privilegded Partnership

Marth C, du Bois A (ENGOG), Schauer C, du Bois A (AGO Study Group), Casado A, Vergote I, del Campo J, Goudopoulou A,
Pujade-Lauraine E, Bruchim I, Colombo N, Pignata S, Ledermann J, Glasspool R, Taskiran C, Fehr M, Cibula D

Int J Gynecol Cancer 2015;25: 1094-1095

European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners – First Update 2015

du Bois A, Reuss A, Pujade-Lauraine E, Pignata S, Ledermann J, Casado A, Sehouli J, Mirza M, Colombo N, Marth C, Witteveen E, del
Campo J, Calvert P, Aravantinos G, Vardar AM, van der Zee AGJ, Korach J, Taskiran C, Fehr M, Glasspool R, Pfisterer J, Cibula D, Vergote I and on behalf of the member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT)

Int J Gynecol Cancer 2015; Jun 9 Epub ahead of print

Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group ROBOT-Study

Farthmann J, Hasenburg A, Weil M, Fotopoulou C, Ewald-Riegler N, du Bois O, Trillsch F, Mahner S, Strauss H-G, Wimberger P, Reuss A, du Bois A

Support Care Cancer, 23(1), 117-23

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarib treatment of ovarian cancer patients

Bachmann HS, Meier W, du Bois A, Kimmig R, Kuhlmann JD, Siffert W, Sehouli J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P

Br J Clin Pharmacol 2015 Nov; 80(5):1139-48. doi: 10.1111/bcp.12688. Epub 2015 Jul 22

Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group Metadatabase

Grabowski J, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A

Gynecol Oncol 2016 Jan 22. pii: S0090-8258(16)30020-8. doi: 10.1016/j.ygyno.2016.01.022. Epub ahead of print

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

P. Harter, A. du Bois, S. Mahner, J. Pfisterer, O. Ortmann, C. Marth, D. Fink, F. Hilpert, U. Wagner, J. Sehouli

Geburtsh Frauenheilk 2016; 76: 147-149

Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO

Klar M, Hasenburg A, Hasanov M, Hilpert F, Meier W, Pfisterer J, Pujade-Lauraine E, Herrstedt J, Reuss A, du Bois A

European Journal of Cancer: Volume 66, October 2016, Pages 114-124
https://www.ejcancer.com/article/S0959-8049(16)32316-4/fulltext

Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial

F. Trillsch, S. Mahner, F. Hilpert, L. Davies, E. García-Martínez, G. Kristensen, A. Savarese, P, Vuylsteke, M. Los, F. Zagouri, L. Gladieff, J. Sehouli, C. Khoon Lee, V. Gebski & E. Pujade-Lauraine

Annals of Oncology 27: 1733-1739, 2016
doi.10.1093/annonc/mdw236
Published online 10 June 2016

Better resource utilization and quality of care for ovarian cancer patients using internet-based pathology review

Kommoss S, Kommoss F, Diebold J, Lax S, Schmid D, Staebler A, du Bois A, Pfisterer J

British Journal of Cancer 116, 287-292 (31 January 2017)

doi:10.1038/bjc.2016.416

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

King MT, Stockler MR, O’Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigau D, Costa DSJ, Friedlander ML for the GCIG Symptom Benefit group

Qual Life Res (2018) 27: 59-74

https://doi.org/10.1007/s11136-017-1729-8, online first 16.12.2017

Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions

Winterhoff B, Kommoss S, Heitz F, Konecny GE, Dowdy SC, Mullany SA, Park-Simon TW, Baumann K, Hilpert F, Brucker S, du Bois A, Schröder W, Burges A, Shen S, Wang J, Tourani R, Ma S, Pfisterer J and Aliferis CF

AMIA Annu Symp Proc. 2018: 1093-1102. Published 2018 Dec 5.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371365/

The end of systematic lymphonodectomy in advanced ovarian cancer

A. Schnelzer, T. Fehm, C. Jackisch für die AGO-Studiengruppe

JOURNAL ONKOLOGIE 1/2020

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

Lee YC, King MT, O’Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann J, Berton-Rigaud D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML, for the GCIG-Symptom Benefit Group

Int J Gynecol Cancer 2022;32:761– 768

Oncological Outcomes of Patients with Cervical Cancer after Fertility Sparing Treatment – FERTISS Retrospective Multicenter Trial

Sláma J, Runnebaum IB, Scambia G, Angeles Fite M, Bahrehmand K, Kommoss S, Fagotti A, Narducci F, Matylevich O, Holly J, Martinelli F, Koual M, Samokhvalova O, El-Balat A, Corrado G, Căpîlna ME, Schröder W, Novàk N, Shushkevich A, Fricová L, Cibula D

Am J Obstet Gynecol. Volume 228, Issue 4,2023, Pages 443.e1-443.e10,
https://doi.org/10.1016/j.ajog.2022.11.1295

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

Philipp Harter, Gerhard Bogner, Luis Chiva, David Cibula, Nicole Concin, Christina Fotopoulou, Antonio Gonzalez-Martin, Frederic Guyon, Viola Heinzelmann-Schwarz, Frederic Kridelka, Sven Mahner, Frederik Marmé, Christian Marth, Philippe Morice, Zoltán Novák, Andrea Papadia, Isabelle Ray-Coquard, Mikuláš Redecha, Andres Redondo, Richard Schwameis, Jalid Sehouli, Manuela Undurraga, Toon Van Gorp, Ignace Vergote

Bull Cancer. 2023 Mar 24; S0007-4551(23)00098-X.
doi: 10.1016/j.bulcan.2023.02.011.

Epub ahead of print

Treatment and survival of patients with malignant ovarian sex cord‐stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT database

Klar M, Plett H, Harter P, Heitz F, Kommoss S, Hartkopf AD, Grube M, Roser E, Sehouli J, Braicu I, Czogalla B, Burges A, Bossart M, Hasanov MF, Link T, Staebler A, Mayr D, Buderath P, Hasenburg A

J Surg Oncol. 2023;1‐8. doi:10.1002/jso.27248

Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients

Richter R, Armbrust R, Woopen H, Hilpert F, Harter P, Sehouli J

ESMO Open 2021 April; 6(2); 100081.
Published online: Jun 24, 2021.
https://doi.org/10.1016/j.esmoop.2021.100176

Psychische Belastung und deren Einflussfaktoren bei Überlebenden von malignen ovariellen Keimzell- oder Keimstrangstromatumoren – eine Analyse der AGO-CORSETT-Datenbank

Bossart M, Plett H, Krämer B, Braicu E, Czogalla B, Klar M, Singer S, Mayr D, Staebler A, du Bois A, Kommoss S, Link T, Burges A, Heitz F, Grube M, Trillsch F, Harter P, Wimberger P, Buderath P, Hasenburg A

Onkologie 2023 · 29:447–454 https://doi.org/10.1007/s00761-023-01334-9

 

Reproductive outcomes after fertility-sparing surgery for cervical cancer – results of the multicenter FERTISS study

Fricová L, Kommoss S, Scambia G, Ferron G, Kocián R, Harter P, Anchora LP, Bats AS, Novàk Z, Walter CB, Raspagliesi F, Lambaudie E, Bahrehmand K, Andress J, Klát J, Pasternak J, Matylevich O, Szeterlak N, Minář L, Heitz F, Căpîlna ME, Runnebaum I, Cibula C, Sláma J

Gynecologic Oncology 2024, Volume 190, 179 – 185,
DOI: 10.1016/j.ygyno.2024.08.020 

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)

Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A.

Int J Gynecol Cancer. 2014 Nov; 24:S5-S8

Gynecologic Cancer Inter Group (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas

Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, Maenpaa J, Kim JW, Pujade-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D.

Int J Gynecol Cancer. 2014 Nov; 24:S9-S13

Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma

Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J, Oza A, Brown J.

Int J Gynecol Cancer. 2014 Nov;24:S14-S19

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary

Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzanzanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A.

Int J Gynecol Cancer. 2014 Nov;24:S20-S25

Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary

Glasspool RM, Gonzáles Martín A, Millan D, Lorusso D, Åvall-Lundquvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, Alexandre J, Ledermann JA.

Int J Gynecol Cancer. 2014 Nov;24:S26-S29

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers

Reed NS, Pautier P, Åvall-Lundqvist E, Choi CH, du Bois A, Friedlander M, Fyles A, Kichenadasse G, Provencher DM, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov; 24:S30-S34

Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary

Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24:S35-S41

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors

Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N.

Int J Gynecol Cancer. 2014 Nov;24:S42-S47

Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors

Brown J, Friedlander M, Backes FJ, Harter P, O’Connor DM, die la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ

5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions

Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RL, Casado Herráez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K, participants of the 5th Ovarian Cancer Consensus Conference

Ann Oncol 2017 Apr 1;28(4):711-717

5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Individualized Therapy and Patient Factors

McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; on behalf of the participants of the 5th Ovarian Cancer Consensus Conference

Ann Oncol 2017 Apr 1;28(4):702-710

5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease

Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zhang R, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference

Ann Oncol 2017 Apr 1;28(4):727-732

5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Clinical trial design for rare ovarian tumours

Leary AF, Quinn M, Fujiwara K, Coleman RL, Kohn E, Sugiyama T, Glasspool R, Ray-Coquard I, Colombo N, Bacon M, Zeimet A, Westermann A, Gomez-Garcia E, Provencher D, Welch S, Small W, Millan D, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference

Ann Oncol 2017 Apr 1;28(4):718-726

6th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, NcNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan David SP, Colombo N, Zang R, Concin N, O’Donnell, Rauh-Hain A, Herrington S, Marth C, Poveda A, Fujiwara K, Stuart GC, Oza AM, Bookman M on behalf of the participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research

Lancet Oncol 2022; 23: e374–84

How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting

Sehouli J, Boer J, Brand AH, Oza A, O‘Donnell J, Bennett K, Glaspool R, Lee C, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, Van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O’Toole S, Lok C, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B, Fujiwara N, Rosengarten O, Nishio H, Kim SI, Mukopadhyay A, Piovano E, Cecere SC, Kohn EC, Mukherjee U, Nasser S, Lindemann K, Croke J, Chen X, Geissler F, Bookman MA

Int J Gynecol Cancer 2024;34:1677-1684

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma

Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I

Int J Gynecol Cancer. 2014 Nov;24:S55-S60

Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas

Hensley ML, Barette BA, Baumann K, Gaffney D, Hamilton AL, Kim JW, Maenpaa JU, Pautier P, Siddiqui NA, Westermann AM, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24:S61-S66

Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma

Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B.

Int J Gynecol Cancer. 2014 Nov;24:S67-S72

Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus

Pautier P, Nam EJ, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24:S73-S77

Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract

Friedlander ML1, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P.

Int J Gynecol Cancer. 2014 Nov;24:S78-S82

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr.

Int J Gynecol Cancer. 2014 Nov;24:S83-S89

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix

Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glaspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K

Int J Gynecol Cancer. 2014 Nov;24:S90-S95

Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma

Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K

Int J Gynecol Cancer. 2014 Nov;24:S96-S101

Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix

Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, Pautier P, Reed NS, Fujiwara K.

Int J Gynecol Cancer. 2014 Nov;24:S102-S108

The Gynecologic Cancer InterGroup (GCIG) consensus recommendations for clinical research in Endometrial Cancer

Creutzberg C L, Kim JW, Eminowicz G, Allanson E, Eberst L, Kim SI, Nout RA, Park jY, Lorusso D, Mileshkin L, Ottevanger PB, Brand A, Mezzanzanica D, Oza A, Gebski V, Pothuri B, Batley T, Gordon C, Mitra T, White H, Howitt B, Matias-Guiu X, Ray-Coquard I, Gaffney D, Small W, Miller A, Concin N, Powell MA, Stuart G, Bookman MA on behalf of the participants of the 2023 Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research

The Lancet Oncology,Vol 25, Issue 9, 2024,pp e420-e431
https://doi.org/10.1016/S1470-2045(24)00192-X

Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup

Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda A, Kim JW, Xiang Y, Berkowitz R, Seckl MJ

Int J Gynecol Cancer. 2014 Nov;24:S109-S116

Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas

Leitao MM Jr, Cheng X, Hamilton AL, Siddiqui NA, Jurgenliemk-Schulz I, Mahner S, Åvall-Lundqvist E, Kim K, Freyer G.

Int J Gynecol Cancer. 2014; Nov24:S117-S122